Altre lingue Abbisko Cayman Limited

Azioni

2256

KYG0028A1085

Mercato chiuso - Hong Kong S.E. Altri mercati azionari 10:08:35 19/04/2024			Variaz. 5gg	Var. 1 gen.
2,9 ^HKD	+1,40%		-1,02%	-20,55%

10/04	L'unità di Abbisko Cayman presenta uno studio preclinico di un farmaco contro il cancro al fegato al meeting annuale dell'AACR	MT
09/04	Abbisko Cayman completa l'arruolamento dei pazienti per la sperimentazione di fase 3 del trattamento del tumore articolare	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Abbisko Cayman's Unit Presents Pre-Clinical Study of Liver Cancer Drug at AACR Annual Meeting	10/04
Abbisko Cayman Completes Patient Enrollment for Phase 3 Trial of Joint Tumor Treatment	09/04
Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib	09/04
Abbisko Cayman's Attributable Loss Narrows as Revenue, Other Gains Rise	14/03
Abbisko Cayman to Buy Back, Cancel Up to HK$100 Million Shares	13/03
Abbisko Cayman Limited commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.	13/03
Abbisko Cayman Limited Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
Abbisko Cayman Completes Dosing for Phase 1 Trials for Lung Cancer Treatment	23/02
Abbisko Cayman Receives $70 Million Upfront Payment for Licensing of Tumor Treatment	06/02
Abbisko Cayman Trustee Buys 6.1 Million Shares Under Restricted Share Scheme	02/02
European Medicines Agency Grants Orphan Drug Designation to Abbisko's Tumor Drug	09/01
Abbisko Therapeutic announces that EMA has granted orphan drug designation for its CSF-1R inhibitor Pimicotinib （ABSK021）	09/01
Abbisko Cayman Doses First Participant in Phase 1 Trial for Anti-Tumor Treatment; Shares Fall 3%	03/01
Abbisko Therapeutics Co., Ltd. Completes the First Patient Dose in the Clinical Trial for Its Next-Generation CD73 Inhibitor ABSK051	03/01
Abbisko Cayman Unit Gets US FDA Fast-Track Status for Tenosynovial Giant Cell Tumor Treatment	14/12
Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib	14/12
Abbisko Therapeutics Announced the Entry into a Licensing Agreement for Pimicotinib (ABSK021) with Merck	04/12
Abbisko Cayman Doses First Patient in Phase 2 Trial for Pancreatic Cancer Treatment	28/11
Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib in China	27/11
China Approves Abbisko Cayman Subsidiary's Clinical Trial for Tumor Drug	09/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Abbisko Cayman Limited

Azioni

2256

KYG0028A1085

Altre lingue

Filtri